These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 11802215)
1. Prognostic value of thymidine phosphorylase expression in breast carcinoma. Yang Q; Barbareschi M; Mori I; Mauri F; Muscarà M; Nakamura M; Nakamura Y; Yoshimura G; Sakurai T; Caffo O; Galligioni E; Dalla Palma P; Kakudo K Int J Cancer; 2002 Feb; 97(4):512-7. PubMed ID: 11802215 [TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732 [TBL] [Abstract][Full Text] [Related]
3. Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Fox SB; Engels K; Comley M; Whitehouse RM; Turley H; Gatter KC; Harris AL Ann Oncol; 1997 Mar; 8(3):271-5. PubMed ID: 9137797 [TBL] [Abstract][Full Text] [Related]
4. Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer. Hata Y; Takahashi H; Sasaki F; Ogita M; Uchino J; Yoshimoto M; Akasaka Y; Nakanishi Y; Sawada Y Breast Cancer; 2000 Jan; 7(1):37-41. PubMed ID: 11029769 [TBL] [Abstract][Full Text] [Related]
5. Correlation between elevated intratumoral thymidine phosphorylase and prognosis of node-positive breast carcinoma undergoing adjuvant doxifluridine treatment. Takahashi H; Maeda Y; Watanabe K; Taguchi K; Sasaki F; Todo S Int J Oncol; 2000 Dec; 17(6):1205-11. PubMed ID: 11078806 [TBL] [Abstract][Full Text] [Related]
6. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. International Breast Cancer Study Group (IBCSG) J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096 [TBL] [Abstract][Full Text] [Related]
7. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer. Nagaoka H; Iino Y; Takei H; Morishita Y Int J Oncol; 1998 Sep; 13(3):449-54. PubMed ID: 9683777 [TBL] [Abstract][Full Text] [Related]
8. Thymidine phosphorylase and breast carcinoma. Yang Q; Yoshimura G; Mori I; Sakurai T; Kakudo K Anticancer Res; 2002; 22(4):2355-60. PubMed ID: 12174926 [TBL] [Abstract][Full Text] [Related]
9. Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer. Toi M; Ueno T; Matsumoto H; Saji H; Funata N; Koike M; Tominaga T Clin Cancer Res; 1999 May; 5(5):1131-7. PubMed ID: 10353748 [TBL] [Abstract][Full Text] [Related]
10. Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast. Engels K; Fox SB; Whitehouse RM; Gatter KC; Harris AL J Pathol; 1997 Aug; 182(4):414-20. PubMed ID: 9306962 [TBL] [Abstract][Full Text] [Related]
11. Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. Han W; Han MR; Kang JJ; Bae JY; Lee JH; Bae YJ; Lee JE; Shin HJ; Hwang KT; Hwang SE; Kim SW; Noh DY BMC Cancer; 2006 Apr; 6():92. PubMed ID: 16608533 [TBL] [Abstract][Full Text] [Related]
12. Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy. Specht K; Harbeck N; Smida J; Annecke K; Reich U; Naehrig J; Langer R; Mages J; Busch R; Kruse E; Klein-Hitpass L; Schmitt M; Kiechle M; Hoefler H Breast Cancer Res Treat; 2009 Nov; 118(1):45-56. PubMed ID: 18925433 [TBL] [Abstract][Full Text] [Related]
13. Chemotherapy and concomitant irradiation in inflammatory breast cancer. Tubiana-Mathieu N; Lejeune C; Bonnier P; Genet D; Adjadj DJ; Berda JF; Muracciole X; Delaby F; Clavere P; Benyoub A; Rhein B; Juin B; Piana L Anticancer Res; 2001; 21(4B):3061-7. PubMed ID: 11712811 [TBL] [Abstract][Full Text] [Related]
14. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Malamou-Mitsi V; Gogas H; Dafni U; Bourli A; Fillipidis T; Sotiropoulou M; Vlachodimitropoulos D; Papadopoulos S; Tzaida O; Kafiri G; Kyriakou V; Markaki S; Papaspyrou I; Karagianni E; Pavlakis K; Toliou T; Scopa C; Papakostas P; Bafaloukos D; Christodoulou C; Fountzilas G Ann Oncol; 2006 Oct; 17(10):1504-11. PubMed ID: 16968874 [TBL] [Abstract][Full Text] [Related]
17. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Koukourakis MI; Giatromanolaki A; Fountzilas G; Sivridis E; Gatter KC; Harris AL Clin Cancer Res; 2000 Feb; 6(2):381-9. PubMed ID: 10690514 [TBL] [Abstract][Full Text] [Related]
18. Thymidine phoshorylase expression in breast cancer: the prognostic significance and its association with other angiogenesis related proteins and extracellular matrix components. Ioachim E Histol Histopathol; 2008 Feb; 23(2):187-96. PubMed ID: 17999375 [TBL] [Abstract][Full Text] [Related]
19. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Gruber G; Greiner RH; Hlushchuk R; Aebersold DM; Altermatt HJ; Berclaz G; Djonov V Breast Cancer Res; 2004; 6(3):R191-8. PubMed ID: 15084243 [TBL] [Abstract][Full Text] [Related]
20. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]